Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. The company's lead compound, XPOVIO (selinexor), is approved in various regions for certain hematologic malignancies and solid tumors. Karyopharm's research and development efforts are dedicated to targeting nuclear transport and related pathways, aiming to develop innovative therapies that address significant unmet medical needs in oncology. By focusing on selective inhibitors of nuclear export (SINE) compounds, Karyopharm seeks to improve patient outcomes and transform the treatment landscape for a range of cancers and other diseases with high morbidity and mortality.